Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,601–3,700 of 3,704
Mokrzecki, S., Mamach, A., Bełc, E., Brzezińska, K., Aleksandrowicz, K., Grodzka, Z., Meszka, M., Król, M., Straszewska, A., Woźniak, A., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6230
The Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain
Kubant, R., & Anderson, G. H. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100737
Targeting the cardiohepatic–metabolic axis: GLP‐1–based and incretin multi‐agonist therapies in MASH
Zhang, Y. W., & Hu, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70828
Sridhar, A., Palmer, E. S., Craig, S. L., Tanday, N., O'Harte, F. P. M., & Irwin, N. (2026) · Diabetologia · doi:10.1007/s00125-026-06863-7
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
Almandoz, J. P., Tchang, B. G., Myers, K., Traina, A., Bhavsar, J., Divino, V. M., Kent, C., & Tadesse-Bell, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71318
Epigenetic determinants of GLP-1 responsiveness: Integrating dietary modulation beyond genetics
Shin, H. R., Kim, T. Y., Min, K., Park, U., Oh, S. W., & Kim, J. K. (2026) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2026.09.004
Goñi, J. A., Sánchez‐Barba, M., López, G. P., Megías, S. M., & Albarrán, O. G. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.09.005
Bone marrow responses to GLP-1 and GIP infusion under hyperglycaemic conditions
Hansen, N. W., Hansen, M. S., Havelund, J. F., Færgeman, N. J., Hartmann, B., Højlund, K., & Frost, M. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag181
Brucar, L. R., Miller, K. M., & Volkow, N. D. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106990
Orforglipron: An Oral GLP-1 Receptor Agonist for Obesity Treatment
Wietholter, J. P., & Terpening, C. M. (2026) · Annals of Pharmacotherapy · doi:10.1177/10600280261486055
Tu, C.-Y., Chen, H.-L., Wu, Y.-H., & Wu, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113573
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
Quantitative insights into tirzepatide and semaglutide using longitudinal systems modeling
Yang, B., Cabrera, O., Mather, K. J., & Sherman, A. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag383
Anti-obesity medications for the management of obstructive sleep apnoea
Collings, T., & Outhoff, K. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4699
Koutouratsas, T., Kalligeros, M., Michael, M., Das, S., Mylonakis, S. C., & Mylonakis, E. E. (2026) · Age and Ageing · doi:10.1093/ageing/afag281 · Cited by 1
Cross-Najafi, A. A., Benavidez, M. C., No, J. J., Ngo, K. C., Redpath, S., Nin, D. Z., Schimpke, S. W., Myers, J. A., Omotosho, P. A., Torquati, A., et al. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.08.047
Practical use of GLP-1-based medications in obesity clinics
Jethwani, P. D., Hallock, R., & Griebeler, M. L. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.011
Hypertensive Disorders of Pregnancy and Cardiovascular-Kidney-Metabolic Syndrome
Ezzat, D., Pabón, M. A., Li, L., Chang, A., Moor, N. D., Yu, Z., Cho, S. M. J., Natarajan, P., Spracklen, C. N., LeBlanc, E. S., et al. (2026) · Hypertension · doi:10.1161/hypertensionaha.126.27750
Seo, J., Choi, S., Kim, N., Kim, H., & Lim, H.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846164
Kaltsas, A., Gkioxaris, V., Giannakas, T., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187313
Ratanpaul, V. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101535
Farmakovijilansın Önemi: GLP-1 Reseptör Agonistlerinin Etkinlik ve Güvenliliği
Kayan, G. T., & Karataş, Y. (2026) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.1976223
GLP-1 medications and health equity: when insurance access determines who benefits
Arif, S., Chaudhary, A., Ullah, S., et al. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag128
Wadhwa, A., Patel, D., Bouras, A., Shah, S., & Daryanani, S. (2026) · Cureus · doi:10.7759/cureus.116758
Shi, Y., Yang, X., Meng, F., Feenstra, K. A., Chen, J., Gu, Z., Gao, X., Yao, W., Dong, G., Gong, L., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c05930
Uppal, H., Spinncickie, A., Grob, P., Adams, D., Klein, D. S., Naseef, G., Schenk, R. S., Chhibber, A., Tis, J. E., & Khanuja, H. S. (2026) · JBJS Reviews · doi:10.2106/jbjs.rvw.26.00116
de Souza, P. F., Patriani, G., & Pacheco, C. M. R. (2026) · Cureus · doi:10.7759/cureus.116779
Ciołkosz, K., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193131
Alshamrani, S., Alqasem, F., Alkhamis, D., & Almulhem, M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1918350 · Cited by 1
Mayne, K. J., Lee, M. M. Y., Sattar, N. A., & Herrington, W. G. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107193
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
Brancato, D., Maggio, V., Vaccaro, F., MURATORE, E., Pirrello, D., Cittadini, E., Patti, A. M., Falco, L. D., Agnello, L., Marcello, C., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109419
Moklesur, M., Islam, M. N., Simon, N. P., Islam, T., Naser, A. Z. M., Hafez, S., & Hasan, R. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104815
GLP-1 Based Therapies for Obesity in Older Adults: Current Evidence and Emerging Treatments
Pendrey, A., Sierra, J. A. R., Alvarez, F. A., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000071
GLP-1 Receptor Agonist Coverage for Obesity in Medicaid and Total GLP-1 Receptor Agonist Utilization
Khanna, R., Wang, M. C., & Venkataramani, A. S. (2026) · JAMA Health Forum · doi:10.1001/jamahealthforum.2026.3353 · Cited by 2
Increased risk of gallstones with obesity and rapid weight loss
Khalil, M., Ciaula, A. D., Baffy, G., Krawczyk, M. J., & Portincasa, P. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102142
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
Khan, M. M., Imam, H., Mondal, N. T., et al. (2025) · TAJ Journal of Teachers Association · doi:10.70818/taj.v38i04.0887
Sisson, E. M., Burns, D., Wheeler, S. E., Akkisetty, K., Christensen, J., & Gupta, G. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261483738
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02229-6
Efficacy and safety of tirzepatide in the treatment of obesity and obesity-associated comorbidities
Sakhnova, E. E., Gavrilova, N. A., Ostroumova, O. D., Кочетков, А. И., Telkova, S. S., & Moryakova, Y. S. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-324
Edvardsson, C. E., Emous, T. A., Witley, S., Ericson, M., Adermark, L., & Jerlhag, E. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70678 · Cited by 1
Shimizu, M. A., Oliveira, M. R., Teixeira, J. M., Gerolamo, A. C. S., & Queiroz, M. M. D. G. (2026) · Brazilian Journal of Medical and Health Sciences · doi:10.64597/eb91a803
Talay, L. A., Hom, J., Tan, M. J., & Ahuja, N. K. (2026) · doi:10.2196/preprints.113195
From Adipose Tissue Dysfunction to Venous Thromboembolism
Boccatonda, A., Brighenti, A., Caturano, A., D’Ardes, D., Acierno, C., Russo, V., Conte, C., Simioni, P., & Campello, E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197500
Trends in Metabolic and Bariatric Surgery Procedure Volume Recorded in MBSAQIP, 2015–2024
Messiah, S. E., Ernest, D. K., Matthew, M., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08962-1
Rescalli, M. B., Fagiolini, A. M., Carmellini, P., Pinzi, M., Castaldo, F., & Cuomo, A. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70066 · Cited by 1
Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract
Samreen, S., & Hutter, M. M. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.08.001
From stress cytokine to drug target: The translational landscape of growth differentiation factor 15
Najjar, N. R., Jonghe, B. C. D., Hayes, M. R., & Doyle, R. P. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105036
Lee, Y. H., & Oh, B. (2026) · Women s Health Nursing · doi:10.4069/whn.2026.09.02
Vikash, F., Ehsan, M., Valencia, S. O., Nadeem, A., Moazzam, E., Butsch, W. S., & Garg, S. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70180
Nava, A. M., & Alencar, M. A. V. D. S. D. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n64-135
Incretin-Based Therapies and the Associated Impact on Bone Health
Łupina, K., Bronowski, M., Dardzińska, N., Jaskulska, P., Nowak, A., Romac, A., RÓŻAŃSKI, P., & Janczura, J. (2026) · International Journal of Pharmacology · doi:10.31083/ijp53550
Garvey, W. T., Ard, J. D., Connery, L. E., Frías, J. P., le Roux, C. W., Pietiläinen, K. H., DINESEN, M., Hagen, B. F., Larsen, L., Hesse, D., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00213-5 · Cited by 2
Self-citationBagheri, K., Buck, E., & Muley, S. (2026) · Cureus · doi:10.7759/cureus.117153
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Self-citationAmjad, M. M., Khan, M. M., Sarwar, F., Ali, A., Ali, M., Bakhash, F., Abid, H., Ibrahim, F., Mustafa, K., Ali, D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71400
Skowron, W., Skowron, M., Łapot, M., Hober, K., Krupnik, D., Bzdak, W., Szwemińska, P., Górak, J., & Neumann, W. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6241
Popa, E., Popa, A. E., Poroch, V., Schreiner, T. G., Slănină, A. M., Poroch, M., Hatneanu, A. M., Ungureanu, M. I., Petroaie, A. D., Bacușcă, A. I., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198738
Li, Q., Yang, T., Jin, G., & Zhou, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1930278
de Souza, F. V., Flexa, B. N. D. S., Schiave, A. L. P. D. S., Silva, A. V., Barros, L. M. D. O. S., Pedrosa, E. K. O., Oliveira, D. M. D., Neves, L. C. M., dos Santos, P. B., Costa, M. N., et al. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n64-142
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Stoicescu, L., Homorodean, C., Gligor, F. G., & Morgovan, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120507
Roy, A., Pabani, U. K., Kyriakou, A., & Elliott, M. K. (2026) · Cureus · doi:10.7759/cureus.117278
Rodríguez-Velásquez, F., Tejada-Giraldo, A. D., Montoya-Durán, A., Goez-Beltran, L., Bonilla, N., Riaño-Pineda, D., Sogamoso-Bohórquez, A., Galves-Cetina, J., & Tuta-Quintero, E. (2026) · Gastrointestinal Disorders · doi:10.3390/gidisord8040060
Tirzepatide: a new treatment for obesity - literature review
Correia, S., Pimenta, A. M., Souto, M. R. S., & Catarino, R. I. L. (2026) · Athena health & research journal. · doi:10.62741/ahrj.v3isuppl.2.199
Obesity, sleep apnea and cancer revisited
Sánchez-de-la-Torre, M., & Gozal, D. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02230-z
Lu, G., Wang, X., Zhuang, H., Wang, X., Zhou, X., & Zhao, G. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179387
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Chaudhari, H. R., Chaudhary, G. A., Gaikwad, Y. B., & Gaikwad, A. (2026) · Geriatric Care · doi:10.4081/gc.2026.15195
Wakeman, M. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017612
GLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?
Pichlerová, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.070
Papadia, F. S., COHEN, R. V., Bernante, P., & Foletto, M. (2026) · Obesity Reviews · doi:10.1111/obr.70240
Endoscopic and Surgical Methods for Weight Loss
Pajtak, A., & Grama, P. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102147
Bruenderman, E. H., Eisa, M., Pearlman, M. Y., & Mundi, M. S. (2026) · Current Surgery Reports · doi:10.1007/s40137-026-00537-4
Chaturvedi, R., Singh, K., Chakole, R., Yadav, B. K., Dhameliya, J., & Joshi, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969433 · Cited by 2
Sibal, R., Balamurugan, G., Aradaib, M., Graham, Y. N. H., & Mahawar, K. K. (2026) · Medicina · doi:10.3390/medicina62101916
Impact of Obesity and Its Treatment on Inflammatory Bowel Disease Outcomes: A Narrative Review
Redavid, C., Pirro, P., Bertin, L., & Savarino, E. V. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17040057
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
GLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease
Kurhaluk, N., Kołodziejska, R., & Ткаченко, Г. М. (2026) · Antioxidants · doi:10.3390/antiox15101283 · Cited by 1
AHMEDOV, A., Karabulut, F., Çiçek, A. C., & Aksay, M. F. (2026) · Journal of Plastic Reconstructive & Aesthetic Surgery · doi:10.1016/j.bjps.2026.09.055
Tauseef, U., Farook, F., Shetty, V. J., Ramos-Ocola, E., Premkumar, C. R., Haider, M., Gandhi, A., Shingala, T. S., Singh, S., TAHIR, M. M., et al. (2026) · Reproductive Medicine · doi:10.3390/reprodmed7040055
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Goldfarb, E., Lifshits, L. A., Abramov, M. M., Bar, D. Z., Barbash, Z., Akiva, E., & Gal, M. (2026) · ACS Nutrition Science · doi:10.1021/acsnutrsci.6c00031 · Cited by 1
Novel Anti-Obesity Drugs: Pharmacokinetics, Pharmacodynamics, and Precision Dosing
Badawoud, A. M., Zaafar, D. K., AlRasheed, H. A., Aldossary, K. M., Alsharif, A. A., & Alsaleh, N. A. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00482-x
Yagudina, R. I., & Tsapko, D. S. (2026) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2026-14-3-263-277
Osiogo, E. O., & Quan, S. F. (2026) · Observations and Insights in Pulmonary and Critical Care · doi:10.2458/001c.170855
Sukurica, E., Sengul, G. F., & Uysal, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71422 · Cited by 2
Obesity care in internal medicine: A gap between recognition and treatment competence
Başaran, N. Ç., Yalçinkaya, F., Uyaroğlu, O. A., & Ünal, S. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107231
Sun, L., Xu, L., Zhou, D., Wang, J., Yin, X., Ye, W., & Tian, L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351589
Shicora, M. C., Ruthes, D. M. J., Henneberg, J. R., & Valério, M. C. J. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n10-026
Paccou, J., Rolvien, T., Hauser, B., Sølling, A. S., Anastasilakis, A. D., & Lems, W. F. (2026) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x261460301
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
Brogaard, E., & Thomsen, S. F. (2026) · Targets · doi:10.3390/targets4040033
He, Y., Ma, T., 邢邯英, Cao, X., Song, F., Pan, Y., & Luping, R. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179418
Vergniory-Trueba, O., & Lobato, C. T. (2026) · Healthcare · doi:10.3390/healthcare14193355
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.